Oncology

For decades, patients with advanced chondrosarcoma had no options. Now, a new drug's journey to the FDA offers a lifeline and a lesson in medical neglect.

Legend Biotech's stunning trial results for an 'in vivo' CAR-T therapy could make advanced cancer treatment faster, safer, and accessible to all.

Lexeo Therapeutics finalizes a pivotal trial for its Friedreich ataxia gene therapy, leveraging a novel trial design and accelerated FDA pathway.

A missed clinical trial endpoint is often the end. For Elicio Therapeutics, a deeper data dive reveals a potential path forward for a high-need patient group.

For 20 years, Montreal's Segal Cancer Centre has quietly built a world-class innovation engine. We dissect its unique model where research, care, and funding converge.

Aussie biotech ENA Respiratory secures crucial US patents for its novel immune modulator, signaling a major strategic move in the multi-billion dollar fight against COPD.

At HLTH Europe, Saudi Arabia's KFSH revealed more than just a radiology AI. It unveiled a full ecosystem, proving how integrated tech transforms patient care.

Akeso's new breast cancer trial is more than a clinical step; it's a key move in a bold strategy to dominate next-gen cancer therapy and capture a lucrative market.

Stunning new US/EU data for BTK inhibitor orelabrutinib signals a major push into Western markets, challenging established blood cancer therapies.

New data shows remarkable response rates for epcoritamab in a vulnerable patient group with limited options, signaling a potential paradigm shift in first-line lymphoma care.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

Atossa Therapeutics secures a crucial capital lifeline. We dissect the deal, its impact on a promising cancer drug, and what it reveals about biotech funding today.

Echo IQ partners with Mayo Clinic to test its AI for cardiac risk in cancer patients, a key move for validation in the burgeoning cardio-oncology sector.

Promising clinical trial results offer hope for cancer patients at risk of permanent, treatment-induced hearing loss, a devastating and common trade-off.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

Jazz Pharma's lung cancer drug Zepzelca fails a key trial, raising regulatory questions. Yet its strength in another setting reveals a complex drug development system.

With its new Series A, Aton Health isn't just growing; it's validating a model where research is seamlessly integrated into routine patient care.

For decades, patients with a rare autoimmune anemia faced a cycle of steroids and relapse. New data on a targeted therapy may finally offer a durable solution.

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?